drugset / Trial / NCT07262268
A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.
Timeline
- Start
- 2026-01-15
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BHV-7000 | Unknown | — | Oral |